XML 12 R50.htm IDEA: XBRL DOCUMENT v2.3.0.15
Intangible Assets and Goodwill (Details) (USD $)
3 Months Ended9 Months Ended9 Months Ended9 Months Ended9 Months Ended9 Months Ended9 Months Ended9 Months Ended9 Months Ended9 Months Ended1 Months Ended9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Dec. 31, 2010
Sep. 30, 2011
In-Process Research and Development [Member]
Dec. 31, 2010
In-Process Research and Development [Member]
Sep. 30, 2011
Trademarks and tradenames [Member]
Dec. 31, 2010
Trademarks and tradenames [Member]
Sep. 30, 2011
Out-licensed patents [Member]
Year
Dec. 31, 2010
Out-licensed patents [Member]
Sep. 30, 2011
Core developed technology [Member]
Year
Dec. 31, 2010
Core developed technology [Member]
Sep. 30, 2011
In-licensed rights and patents [Member]
Year
Dec. 31, 2010
In-licensed rights and patents [Member]
Sep. 30, 2011
Assembled workforce [Member]
Year
Dec. 31, 2010
Assembled workforce [Member]
Sep. 30, 2011
Distribution rights [Member]
Year
Dec. 31, 2010
Distribution rights [Member]
Sep. 30, 2011
Avonex [Member]
Sep. 30, 2011
VP1 Protein [Member]
Jul. 31, 2011
Acorda [Member]
Sep. 30, 2011
Acorda [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]                       
Estimated Life     Up to 15 years upon commercialization Indefinite               
Cost and Net     $ 110,900,000$ 110,900,000$ 64,000,000$ 64,000,000              
Intangible assets                       
Estimated Life (In Years)         12   14 4 2     
Estimated Life, Minimum (In Years)           15           
Estimated Life, Maximum (In Years)           23           
Cost         578,000,000578,000,0003,005,300,0003,005,300,00047,100,0003,000,0002,100,0002,100,00012,700,00012,700,000    
Total intangible assets, gross3,820,100,000 3,820,100,000 3,776,000,000               19,200,000  
Accumulated Amortization(2,161,000,000) (2,161,000,000) (2,003,200,000)    (381,100,000)(350,200,000)(1,761,800,000)(1,636,900,000)(3,300,000)(1,300,000)(2,100,000)(2,100,000)(12,700,000)(12,700,000)    
Net         196,900,000227,800,0001,243,500,0001,368,400,00043,800,0001,700,00000001,230,900,000   
Intangible assets, net1,659,114,000 1,659,114,000 1,772,826,000                  
Intangible Assets and Goodwill Additional (Textuals) [Abstract]                       
Net book value of the core technology intangible asset related to our AVONEX product         196,900,000227,800,0001,243,500,0001,368,400,00043,800,0001,700,00000001,230,900,000   
Amortization of intangible assets for each of next five years, Minimum  150,000,000                105,000,000   
Amortization of intangible assets for each of next five years, Maximum  200,000,000                155,000,000   
Expected usage-based royalties to be earned through 2016 from license agreement                    53,300,000  
Intangible asset recognized to reflect the total of upfront and other time-based milestone payments expected to be made3,820,100,000 3,820,100,000 3,776,000,000               19,200,000  
Milestone payment payable to Acorda Therapeutics, Inc. (Acorda)                     25,000,000 
Amount due on next expected milestone payment                      15,000,000
Net sales over four consecutive quarters  100,000,000                    
Intangible Assets and Goodwill (Textuals) [Abstract]                       
Amortization of acquired intangible assets49,300,00053,500,000157,700,000155,600,000                   
Accumulated impairment loss on goodwill$ 0 $ 0